-
Mashup Score: 1Baseline Immunologic State Affects CAR T-Cell Response in LBCL | Blood Cancers Today - 2 month(s) ago
The baseline immunologic state of a patient with large B-cell lymphoma could affect response to CAR T-cell therapy through modulation of the T-cell apheresis product composition.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Liso-Cel Shows Clinical Benefit in Relapsed/Refractory LBCL - 6 month(s) ago
Jeremy Abramson, MD, discusses findings from the TRANSFORM study of lisocabtagene maraleucel vs standard of care treatment in patients with relapsed or refractory large B-cell lymphoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
In this video, Jeremy Abramson, MD, reviews data from the TRANSFORM study of liso-cel vs standard of care treatment in patients with relapsed or refractory #LBCL. @MGHCancerCenter https://t.co/57Z6ox8O0F
-
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Lunning, DO, and participants discussed how they approach treatment for a patient with diffuse large B-cell lymphoma who relapsed 8 months after primary therapy.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Matthew A. Lunning, DO, and participants discussed how they approach treatment for a patient with diffuse #LBCL who relapsed 8 months after primary therapy. #lymsm | @lymphomaphilia @NebraskaMed https://t.co/ZL5dLDOstT https://t.co/unDfdnyupX
-
-
Mashup Score: 2Emerging CAR T-Cell Therapies in Large B-Cell Lymphoma - 7 month(s) ago
In an interview with Targeted Oncology, Frederick Locke, MD, discussed the mechanism of action of 2 allogeneic CD19-directed CAR T-cell products and next steps for their evaluation for the treatment of patients with LBCL.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Frederick Locke, MD, provided an overview on 2 allogeneic CD19-directed CAR T-cell products, ALLO-501 and ALLO-501A, and their potential role in #LBCL. #lymsm | @MoffittNews @DrFredLocke https://t.co/dNmh3HyKBH https://t.co/3aBHCJSn5u
-
-
Mashup Score: 0Fall 2023 SWOG Group Meeting | SWOG - 8 month(s) ago
Meeting Booklet (PDF available late September) Starting this fall, the meeting agenda book will be provided in PDF form only. Printed agenda books will NOT be provided in Chicago. A printed agenda pocket card/tri-fold brochure WILL be provided in Chicago, as at past meetings. A new mobile app with meeting details will also be available for download to your phone or tablet in late September….
Source: www.swog.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Be sure to attend the kickoff session for this S2207 trial at the @SWOG fall group meeting, Thurs, Oct 12, 1-2:30 pm CT, Chicago and online! Valuable info for all who will enroll patients to this study in #LBCL. https://t.co/AJ0rQQnL9o #SWOGonc https://t.co/VtxFYTasnH
-
-
Mashup Score: 1Fall 2023 SWOG Group Meeting | SWOG - 8 month(s) ago
Meeting Booklet (PDF available late September) Starting this fall, the meeting agenda book will be provided in PDF form only. Printed agenda books will NOT be provided in Chicago. A printed agenda pocket card/tri-fold brochure WILL be provided in Chicago, as at past meetings. A new mobile app with meeting details will also be available for download to your phone or tablet in late September….
Source: www.swog.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Fall 2023 @SWOG Group Meeting, Oct 11-14, Chicago, offers kickoff sessions for S2207 (#lymphoma #LBCL) & S2209 (#myeloma #MMSM), an update forum on SWOG Clinical Trials Partnerships (CTP) studies, a celebration of @SupportingSWOG, & much more! Registered? https://t.co/AJ0rQQndjQ https://t.co/v5pCefg9Pq
-
-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Approximately 40% of patients with large B-cell #lymphoma (LBCL) face relapse after treatments like R-CHOP or DA-EPOCH-R. Axicabtagene ciloleucel, a CAR T-cell therapy, is being investigated as a first-line treatment for high-risk LBCL patients. https://t.co/jcC8gA0hyq #LBCL https://t.co/2YJPaNlRTw
-
-
Mashup Score: 0Axi-Cel Outperforms Standard Second-Line Treatment for LBCL - 10 month(s) ago
Second-line treatment with axicabtagene ciloleucel can improve overall survival when compared to standard care in patients with relapsed or refractory large B-cell lymphoma.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Second-line treatment with axi-cel can improve OS when compared to standard care in patients with R/R large B-cell #lymphoma. Presented at @ASCO #ASCO23. https://t.co/4Lne92CyOU #LBCL
-
-
Mashup Score: 0Axi-Cel Shows Superior Overall Survival Data vs Standard of Care in LBCL - 10 month(s) ago
Researchers sought to determine whether axi-cel would improve overall survival rates in patients with LBCL.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Axi-cel appears to improve OS rates compared with historical standards among patients with R/R large B-cell #lymphoma. Presented at @ASCO #ASCO23, published in @HematologyAdv. https://t.co/XI1H1VP7Qr #LBCL #HemOnc
-
-
Mashup Score: 0JNCCN 360 - B-Cell Lymphomas - 5-Year Follow-up From ZUMA-1: Axicabtagene Ciloleucel in Resistant LBCL - 10 month(s) ago
By: Joshua Swore, PhD Posted: Wednesday, May 31, 2023 Axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, has curative potential for patients with refractory large B-cell lymphoma (LBCL), according to an article published in the journal Blood. In this 5-year follow-up of the…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
5-Year Follow-up From ZUMA-1: Axicabtagene Ciloleucel in Resistant #LBCL: https://t.co/eMq0TE4lku #lymsm https://t.co/aIV6I4raHo
-
The baseline immunologic state of a patient with #LBCL could affect response to CAR T-cell therapy, according to a study led by @Dr_KatieM of @DanaFarber. Read more: https://t.co/H4wQmGf2Bz https://t.co/M2FhiQQIiC